

QOPI® REPORTING TRACKS

QOPI Certification	LMIC ¹	LMIC Tier 2 ²	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X	X	X	Core	1	Pathology report confirming malignancy	
X	X	X	Core	2	Staging documented within one month of first office visit	NQF Endorsed #0386 (adapted)
	X	X	Core	3	Pain assessed by second office visit	NQF Endorsed #0383/#0384 (adapted)
X		X	Core	6	Pain addressed appropriately (defect-free measure 3, 4a, 5)	NQF Endorsed #0383 (adapted)
X			Core	6a	Pain assessed on either of the two most recent office visits	NQF Endorsed #0383/#0384 (adapted)
X	X	X	Core	9	Documented plan for chemotherapy, including doses, route, and time intervals	
X		X	Core	10	Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration	
X			Core	11	Chemotherapy intent discussion with patient documented	
	X	X	Core	12	Number of chemotherapy cycles documented (used in LMIC Track only)	
X			Core	13oc4a	Documented plan for oral chemotherapy: Dose	
X			Core	13oc4b	Documented plan for oral chemotherapy: Administration schedule (start day, days of treatment/rest and planned duration)	
X		X	Core	16	Patient consent for chemotherapy (combined measure, 14, or 15)	
X		X	Core	21aa	Smoking status/tobacco use documented in past year	NQF Endorsed #0028 (adapted)

*QOPI® Certification Measure

1) Low-Middle Income Countries Track

2) Low-Middle Income Countries Track Tier 2; new for 2024

Copyright© 2024 American Society of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the Society. Updated: 01/05/2024

QOPI® REPORTING TRACKS

QOPI Certification	LMIC ¹	LMIC Tier 2 ²	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X			Core	24	Patient emotional well-being assessed by the second office visit	
X			Core	25	Action taken to address problems with emotional well-being by the second office visit	
X		X	Core	25b	Height, Weight, and BSA documented prior to chemotherapy	
X			Symptom/ Toxicity	30	Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents	
X			Symptom/ Toxicity	31	Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Lower Score – Better)	
X			Symptom/ Toxicity	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age	
X			Breast	53	Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) and IB - III ER/PR negative breast cancer	NQF Endorsed #0559 (adapted)
X			Breast	54	Test for Her-2/neu overexpression or gene amplification	NQF Endorsed #1878 (adapted)
X			Breast	59	Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage IA(T1c) and IB - III ER or PR positive breast cancer	NQF Endorsed #0220/#0387 (adapted)
X			Colorectal	68	Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage III colon cancer	NQF Endorsed #0223/#0385 (adapted)
X			Colorectal	74	RAS (KRAS and NRAS) testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy	NQF Endorsed #1860 (adapted)
X			NSCLC	84	Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC	

*QOPI® Certification Measure

1) Low-Middle Income Countries Track

2) Low-Middle Income Countries Track Tier 2; new for 2024

Copyright© 2024 American Society of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the Society. Updated: 01/05/2024

QOPI® REPORTING TRACKS

QOPI Certification	LMIC ¹	LMIC Tier 2 ²	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X			NSCLC	88	Patients with Stage IV NSCLC with adenocarcinoma histology with an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy	
X			NSCLC	89a	GCSF administered to patients who received chemotherapy for metastatic NSCLC cancer (Lower-Score- Better)	

*QOPI® Certification Measure

1) Low-Middle Income Countries Track

2) Low-Middle Income Countries Track Tier 2; new for 2024

Copyright© 2024 American Society of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the Society. Updated: 01/05/2024